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Endometrial cancer is themost commonly diagnosed gynecologicmalignancy in the United
States. Awell recognized disparity by race in both incidence and survival outcome exists for
this cancer. Speciﬁcally Caucasians are about two times more likely to develop endometrial
cancer than are African-Americans. However, African-American women are more likely to
die from this disease than are Caucasians. The basis for this disparity remains unknown.
Previous studies have identiﬁed differences in the types and frequencies of gene muta-
tions among endometrial cancers from Caucasians and African-Americans suggesting that
the tumors from these two groups might have differing underlying genetic defects.We per-
formed a gene expression microarray study in an effort to identify differentially expressed
transcripts between African-American and Caucasian women’s endometrial cancers. Our
gene expression screen identiﬁed a list of potential biomarkers that are differentially
expressed between these two groups of cancers. Of these we identiﬁed a poorly char-
acterized transcript with a region of homology to phospho serine phosphatase (PSPH )
and designated phospho serine phosphatase like (PSPHL) as the most differentially over-
expressed gene in cancers from African-Americans. We further clariﬁed the nature of
expressed transcripts. Northern blot analysis conﬁrmed the message was limited to a
transcript of under 1 kB. Sequence analysis of transcripts conﬁrmed two alternate open
reading frame (ORF) isoforms due to alternative splicing events. Splice speciﬁc primer
sets conﬁrmed both isoforms were differentially expressed in tissues from Caucasians
and African-Americans.We further examined the expression in other tissues from women
to include normal endometrium, normal and malignant ovary. In all cases PSPHL expres-
sion was more often present in tissues from African-Americans than Caucasians. Our data
conﬁrm the African-American based expression of the PSPHL transcript in endometrial
cancer and also identify its expression in other tissues from African-Americans including
ovary and ovarian cancer. PSPHL represents a candidate gene that might inﬂuence the
observed racial disparity in endometrial and other cancers.
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INTRODUCTION
A racial disparity in incidence and survival exists for many
human cancers. Understanding and addressing the reasons for
these disparities is critical for reducing cancer burdens. A well
described disparity in both incidence and survival outcome exists
for endometrial cancer. Population based studies using data from
both the National Cancer Data Base and Surveillance, Epidemi-
ology, and End Results (SEER) have consistently shown that
Caucasians (CA) are more likely to develop this cancer than are
African-Americans (AA) even after controlling for hysterectomy
(Hicks et al., 1998; Sherman and Devesa, 2003; Sherman et al.,
2005). However, African-American women are about two times
more likely to die from their disease than are Caucasians (Hicks
et al., 1998; Ghafoor et al., 2002). The reasons underlying these
disparities are complex and include social, cultural and biologic
factors (Maxwell and Risinger, 2006). Several molecular genetic
studies have identiﬁed differences in the prevalence of certain
gene mutations or expression aberrations in cancers from AA
and CA women. For example, the TP53 tumor suppressor gene is
mutated more frequently in endometrial cancers fromAA women
(Kohler et al., 1996). Similarly the HER2/Neu oncogene is more
frequently up-regulated in endometrial cancer from AA women
(Santin et al., 2005). In addition, a speciﬁc chromosome gain on
chromosome one is more frequent in endometrial cancers from
www.frontiersin.org July 2012 | Volume 2 | Article 65 | 1
Allard et al. PSPHL expression in endometrial cancers from African-Americans
AA women (Morrison et al., 2010). Epigenetic methylation of
the ribosomal DNA is also less prevalent in endometrial cancers
from AA women (Powell et al., 2002). TP53, rDNA, and HER2
events are tied to more aggressive behavior and adverse outcome
in endometrial cancer, suggesting they may be responsible in part
for the outcomes disparity for AA women. In contrast, the PTEN
tumor suppressor gene ismore frequentlymutated in cancers from
CA and is associated with a more favorable outcome (Maxwell
et al., 2000). It is important to note that African-Americans more
often have non-endometrioid cancers and the above referenced
gene changes are often more frequently associated with speciﬁc
histotype e.g., TP53 and serous and PTEN with endometrioid
type (Kohler et al., 1996; Maxwell et al., 2000; Wright et al.,
2009).
Recently, we performed transcript expression studies in
endometrial cancers (Risinger et al., 2003, 2005; Maxwell et al.,
2005; Ferguson et al., 2006). These studies showed distinct expres-
sion related to histologic type as well as identifying transcripts
associated with the microsatellite instability phenotype. In this
study we speciﬁcally compared stage and grade matched endome-
trial cancers fromAA and CA patients to identify whether distinct
transcripts were associated with the race of the patient and, if so,
whether these could serve as candidates for diagnosis, prognosis,
or intervention. A previous study using a very similar study design
found no global differences between AA and CA but did identify
a small sub-set of genes differentially expressed. Although global
differences between the two groups are not evident, we do identify
a number of statistically differentially expressed transcripts, a sub-
set of which were validated by quantitative real time PCR. Among
those validated was that encoded by the gene for phosphoserine
phosphatase like (PSPHL), which was found to be prominently
expressed in endometrial cancer specimens from AA women and
cloned an additional splice variant also preferentially expressed in
AA women.
RESULTS
GENE EXPRESSION OF AFRICAN-AMERICAN AND CAUCASIAN
ENDOMETRIAL CANCERS
We performed a hybridization-based transcript expression analy-
sis (Affymetrix) on a set of endometrial cancer specimens that
were controlled for stage and grade and examined the global tran-
script expression of these cancers using multidimensional scaling.
Cancers representing the groups were not found to be distinct
indicating that race was not the chief determinant of gene expres-
sion between these two groups (Figure 1A). Class comparison
tests between AA and CA indicated 341 transcripts at p< 0.005
with a global test p-value of 0.061. We further examined the data
using principal component analysis (PCA). The ﬁrst two principal
components (PCs) explaining highest variance did not distinguish
AA and CA classes. However, a sub-set of CA cases partially seg-
regated from AA cases along PC #3 which explains only 7.2%
of the total variance (Figure 1B). Despite the lack of global differ-
encewedeterminedwhich transcriptswere differentially expressed
between these groups by paired t -tests to control for histology,
stage, and grade variations. We noted a total of 263 genes (325
transcripts) at p< 0.005 (Table S1 in Supplementary Material) –
66 of these marked by at least a twofold change are depicted in
Figure 2.
QUANTITATIVE VALIDATION OF DIFFERENTIALLY EXPRESSED
TRANSCRIPTS
Findings on gene expression microarrays require validation using
alternate sample sets and more quantitative methodologies. We
performed quantitative real time (qRT) PCR to validate the
array ﬁndings for a sub-set of transcripts identiﬁed. Speciﬁ-
cally we examined the Insulin-like Growth Factor Receptor 1,
(IGFR1) Mucin 20, (MUC20), Ras Related Associated with Dia-
betes, (RRAD), and the Phosphoserine Phosphatase (PSPH ) genes
using qRT-PCR. Data from these assays performed on a panel of
FIGURE 1 | Comparison of global expression profiles of endometrial
cancers fromAfrican-American and Caucasian women. (A)
Multidimensional scaling using 1-correlation as distance metric did not
distinguish the classes. (B) Principal component analysis indicates
differential expression along PC #3 that explains 7.2% of the total variance
may not be statistically signiﬁcant. The expression data of about 18,500
transcripts detected in at least half of the cases were used for these
analyses.
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FIGURE 2 | Heat map of 66 transcripts differentially expressed betweenAfrican-American and Caucasian by twofold and p <0.005. Expressions shown
are mean centered. The red indicates increased and green down-regulated expression while black indicates mean value.
endometrial cancers fromAAandCA conﬁrmed the array ﬁndings
for IGF1R,MUC20, and RRAD, but interestingly, qRT-PCR utiliz-
ing primers targeted to PSPH did not (Figure 3). Close inspection
of the (Affymetrix) probe sequence indicated that the microar-
ray probes were actually situated in a poorly described sequence
locus on the opposite arm of chromosome 7. This transcript is
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FIGURE 3 |TaqMan quantitative PCR validation of expression levels of
IGF1R, MUC20, RRAD, PSPH, and PSPHL in endometrial cancers from
Caucasian (n =14) and African-American (n =10) women is shown in top
row.The expressions were normalized to endogenous β-actin and then the
ratios to Caucasian are shown. Bottom row is from array data of same
samples.
alternatively designated as CO9 or PSPHL due to sequence iden-
tity to parts of PSPH. This observation motivated the design of
primers speciﬁc for PSPHL and re-analysis of the endometrial
cancer specimens by qRT-PCR deﬁnitively demonstrates elevated
expression of this transcript in AA as compared to CA patients
(Figure 3).
OVERLAP WITH PREVIOUS PUBLISHED MICROARRAY DATA
We compared the differentially expressed genes with those
described by Ferguson et al. (2006). We noted that probe set mis-
annotated for PSPH was the single overlapping gene when we
compared those transcripts identiﬁed at p< 0.001 (Figure 4) This
fact and the general observation that there were few genes identi-
ﬁed and those with low p-values exhibit small fold differences for
most genes further suggesting the effect of race on gene expres-
sion is not prominently delineated from this type of microarray
analysis.
TRANSCRIPTS FROM THE PSPHL GENE
Deposited transcript information for this locus is represented by
one mRNA and three spliced ESTs (BG183407, BG196884, and
BX380670). In addition a publication described a related PSPH
sequence as the CO9 gene and published a 840 bp long sequence
with homology to exons of PSPH and matched the 3′ end of the
consensus PSPHL transcript deposited in NCBI (Planitzer et al.,
1998). To clarify the nature of the over-expressed sequence we
ampliﬁed fetal cDNA using primers homologous to the predicted
ORF of PSPHL. This PCR gave two prominent bands following
FIGURE 4 | Comparison of the numbers of differentially expressed
transcripts from this work with the report of Ferguson et al. (2006).
Only the transcripts altered by 1.4-fold at p <0.001 between the
endometrial cancers from African-American and Caucasian are shown.
PSPHL is found to be highly expressed in African-American cases in both
studies.
agarose gel electrophoresis (data not shown). These PCR prod-
ucts were cloned in the pENTR Topo vector, resultant individual
colonies isolated, and plasmid clones were sequenced. We con-
ﬁrmed the sequence of an isoform identical to the PSPHL ORF as
well as a second isoform with an apparent alternative splice that
matched no other deposited RNA. These sequences contain ORFs
that predict small peptides with a similar n-termini with a PSPH
homologous region but differing in their c-terminal end due to
frame shifting of the ORF (Figure 5). Potential peptides generated
from the two longest ORF from these isoforms are very small at 72
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FIGURE 5 | (A) mRNA homology of splicing variants of PSPHL PSPHL_A
mRNA sequence (839 bp) is 100% match to the PSPH homolog C09 gene
(503 bp) and L-3-phosphoserine-phosphatase homolog (839 bp; AJ001612).
(B) Protein homology of splicing variants of PSPHL PSPHL_B has a novel
spliced 122 bp sequence in the middle of PSPHL_A form alters the reading
frame and utilizes a different stop codon.
aa and 91 aa.We therefore examinedwhether thePSPHL transcript
was incompletely cloned.We determined the expression of PSPHL
in a panel of endometrial cancer cell lines using quantitative PCR
and then probed RNA from some of these using a cDNA probe
speciﬁc to PSPHL to determine the size of the PSPHL message.
In cell lines expressing the transcript we noted a message that was
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less than 1 kb (Figure 6) suggesting that longer forms of PSPHL
were not expressed in these endometrial cancers andmissing from
databases. We next performed 5′ and 3′ prime rapid ampliﬁcation
of cDNA ends (RACE) on a cDNA sample prepared from a pool
of uterine carcinomas from African-Americans. Resultant clones
FIGURE 6 | (A) Expression levels of PSPHL in uterus cancer cell lines using
quantitative PCR. (B) Northern blot analysis using PSPHL speciﬁc probes,
(1) HOUA (2) HHUA (3) AN3CA (4) HEC 59 (5) HEC 1A (6) KLE (7) NCI-EC1.
Ethidium Bromide stain of the 18 s subunit for loading control.
were sequenced and compared to the deposited concensus PSPHL
sequence in NCBI. There were two forms of PSPHL identiﬁed one
of which matched to the consensus sequence. However the sec-
ond matched the form we identiﬁed from ORF speciﬁc PCR and
has not been described, which we designated form B. Our data
indicate that two spliced forms of PSPHL were expressed in these
cancers. The length of message on Northern analysis and cloned
transcripts are consistentwith two forms expressed in these tissues.
A diagram of the PSPHL locus and predicted peptides is shown in
Figure 5.
PSPHL EXPRESSION IN NORMAL AND TUMOR TISSUES
We further explored the expression of PSPHL in additional human
tissue samples. We wished to determine if PSPHL was expressed
in normal endometrium or if there was evidence that supported
whether this transcript is differentially expressed in cancers from
African-Americans.We examined PSPHL expression in a set of 13
tissue specimens of normal endometrium with seven being from
AA and six from CA. Expression of PSPHL was more prominent
in the AA specimens (Figure 7). We also found that PSPHL form
B was expressed more frequently in AA tissues (Figure 7). To fur-
ther examine PSPHL expression we examined normal and cancer
tissues from the ovary.We examined a set of stage IIIc serous ovar-
ian cancers and again noted a race difference (Figure 8). Similar
to data from the endometrium, normal ovary tissue from AA dis-
played an elevated level of the transcript for PSPHL whereas there
was no signiﬁcant difference in levels of PSPH (Figure 8), with
isoform B being elevated in AA (Figure 8). We next conﬁrmed
in a public array set of 39 serous ovarian cancers the expression
of PSPHL preferentially in AA cancers compared to CA and no
change in PSPH (Figure 9).
FIGURE 7 | Relative expression levels of PSPHL-A (top) and PSPHL-B (bottom) in normal endometrium for Caucasian and African-American women.
Left: individual cases; Right: averages. PSPHL-A: AA/CA ratio = 279, p =0.007; PSPH:L-B AA/CA ratio = 146, p =0.0065.
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FIGURE 8 |TaqMan validation of expression levels for Caucasian
(CA) and African-American (AA) women: (A) PSPHL-A in ovarian
cancers, (B) PSPHL-A in normal ovary, (C) PSPHL-B isoform in
normal ovary and (D) PSPH in normal ovary. Left Individual cases;
Right: geometric averages. Error bars indicate standard error. The inset
of (C) shows ratios in expanded scale. AA/CA ratios: A=233. B =139.
C =92, D =0.78; p-values A=1.24×10−7; B =0.00075; C =0.001;
D =0.46.
PSPHL PROTEIN
Phosphoserine phosphatase (PSPH) is a 225 amino acid enzyme
responsible for catalyzing the last step in the biosynthesis of serine
from carbohydrates. The two transcripts correlating to putative
phosphoserine phosphatase like protein (PSPHL) could encode
a 72 or 91 amino acid homolog of PSPH. However, no evidence
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FIGURE 9 | Relative expression levels of (A) PSPHL and (B)
PSPH in serous ovarian cancers from six African-American
(AA) and 33 Caucasian (CA) women estimated using array
data from Berchuck et al. (2009). (C,D) Geometric averages.
PSPHL: AA/CA ratio = 5.56, p =0.00046; PSPH: AA/CA ratio = 1.20,
p =0.39.
exists to date demonstrating a protein product from PSPHL. We
cloned and expressed a tagged version of PSPHL in E. coli and a
total lysate resolved by 1D PAGE and Coomassie staining revealed
evidence of PSPHL at the predicted mass of 7.8 kDa (not shown).
The prominent protein band was excised, in-gel digested with
trypsin and peptides and analyzed by nanoﬂow reversed-phase liq-
uid chromatography (nRPLC) coupled online with tandem mass
spectrometry. The collision-induced dissociation spectra resulting
from this analysis were searched using SEQUEST (ThermoFisher
Scientiﬁc) against the human UNIPROT proteome database. The
results conﬁrmed the presence of a number of PSPHL peptides
conﬁrming the presence of the PSPHL gene product by mass
spectrometry. Shown in Figure 10 is the CID spectrum from
a unique peptide from PSPHL (MISHSELR), which unambigu-
ously displays prominent fragment ions from the core sequence
of the peptide. We utilized this methodology in attempts to detect
the PSPHL gene product in human endometrial cancer cells. We
examined cell lines with negative and positive endogenous PSPHL
transcript expression. We did not identify any PSPHL peptides
in either sample supporting the conclusion that the endogenous
PSPHL is not found at the protein level (Figure 11). Furthermore
it is notable that there exists no evidence in the literature that the
PSHPL gene encodes for a functional protein product. Further,
this gene has been annotated as likely being a pseudogene by the
European Bioinformatics Institute1.
1http://www.uniprot.org/uniprot/O15172.
EXPRESSION RELATED TO OUTCOME IN GYNECOLOGIC CANCER
African-Americans exhibit signiﬁcant health disparities compared
to Caucasians in the United States. We examined two array data
sets of endometrial and ovarian cancer to determine whether there
were differences in expression of PSPHL related to outcome. First
we examined a set of 131 uterine cancers for which we knew race
and outcome and that had been previously arrayed on Affymetrix
chips. These data include 26 AA cases with 3 deaths and 105 CA
cases with 10 deaths in the study period of about 16 years between
1989 and 2007. However, we noted few deaths overall in this group
of cancers and even fewer among African-Americans. The small
number of events limited the strength of survival analysis. We
examined the effect of race in this dataset and noted that Cau-
casians actually survived better (Figures 12A,D) though the result
is not statistically signiﬁcant. We conﬁrmed higher expression of
PSPHL in African-Americans cancers in this data set regardless
of histologic type (Figures 13 and 14). However, when we exam-
ined the overall association of PSPHL expression in this dataset we
found there was no difference in survival between high expression
and low expression of PSPHL or PSPH (Figures 12B,C).
We next examined a data set of short- and long-term sur-
vivors of advanced serous carcinoma of the ovary. We con-
ﬁrmed the higher expression of PSPHL in African-Americans’
cancers but again noted an insigniﬁcant association with outcome
(Figures 12E,F). We did note a high level of PSPHL expression
in some short-term survivors but the number of cases was small
and when the data are entered in a continuous model of survival
statistically insigniﬁcant (Figure 14).
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FIGURE 10 | Collision-induced dissociation spectrum of MISHELR, a unique peptide derived from trypsin digestion of PSPHL.
FIGURE 11 | Detection of the diagnostic MISHELR peptide of PSPHL in HOUA endometrial cancer cell lysate.Top panel. Red oval indicates the area where
the peptide should be detected, its absence indicating no PSPHL protein in this extract. Bottom shows the recombinant peptide when spiked in the extract.
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FIGURE 12 | Survival analysis of endometrial cancers using 131 cases
(AA-26, CA-105) in which there were I3 (AA-3, CA-10) deaths in the study
period of 16 years.Top row Kaplan–Meier curves for (A) Race (B) PSPHL,
and (C) PSPH. Up and down-regulations are from median level. The p-values
are not statistically signiﬁcant due to small number of events available for the
analysis. (D–F) Cox regression analysis of same data showing estimated
survival curves: (D) for AA and CA, (E) minimum and maximum signal levels
of PSPHL and (F) minimum and maximum signal levels of PSPH.
FIGURE 13 | Expression of PSPHL in endometrial cancers from
Caucasian. African-American women and normal uterus.
DISCUSSION
A well recognized racial disparity in incidence and survival out-
come exists for endometrial cancer patients in the United States.
The racial disparity in outcome is likely multi-factorial. Some
reasons include access and utilization of healthcare that may be
due to unequal treatment and mistrust of the medical commu-
nity, as well as differences in cultural acceptance of disease and its
fate. However, some authors have suggested that the disparity can-
not be explained in total by non-biological factors (Sherman and
Devesa, 2003). African-American women tend to be diagnosed
with more advanced disease and with adverse histologic types and
higher grade, than do Caucasians. These factors are reﬂective of a
more aggressive type of cancer (Steinhorn et al., 1986). Although
the endometrial cancers diagnosed in African-American women
are often non-endometrioid and poorly differentiated, survival
remains worse for African-Americans in investigations that con-
trol for stage, grade, histology, and surgical treatment (Randall and
Armstrong, 2003).
Molecular genetic data indicates differences in the kinds of
mutations that occur in tumors from each group. Several stud-
ies have examined the mutational frequency of genes commonly
mutated and involved in the pathogenesis of endometrial can-
cer (Risinger et al., 1997; Tashiro et al., 1997; Suzuki et al., 1998;
Stambolic et al., 2000). In addition to differences in DNA muta-
tions several studies have examined other changes to include
microsatellite instability, HER2/NEU over expression, and rDNA
methylation (Maxwell et al., 2000; Powell et al., 2002; Santin et al.,
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FIGURE 14 | (A) Differential expression of PSPHL in ovarian cancers of
short-term survivors. (B) Relative expressions of PSPH in the same ovarian
cancers (data from Berchuck et al., 2009). Differential expression of PSPH in
endometrial cancers: (C) by stage and (D) by histologic type. AA,
African-American; CA, Caucasian; Signal, geometric average signal from
Affymetrix micro arrays.
2005). Based in part on these observations Ferguson et al. (2006)
examined the gene expression from African-American and Cau-
casian women and found few statistically differentially expressed
genes.We performed a similar type studywhich is described in this
manuscript and found a few more statistically signiﬁcant genes
but largely conﬁrm that underlying expression due to the patients
race was not apparent in global expression.We did identify a set of
genes that were statistically signiﬁcant and might represent can-
didates for evaluation on racial disparity of this disease. However
we chose to focus most of our validation efforts on the single
probe set that was signiﬁcantly changed in both sets of data and
represented not only robust statistical signiﬁcance but a signiﬁ-
cant fold change in expression as well. Interestingly the probe set
targeted a poorly described transcript with homology to PSPH.
PSPH, Phosphoserine phosphatase (PSP) normally functions in
the conversion of l-phosphoserine to l-serine. Serine is one of
the amino acids necessary for protein and nucleotide synthesis.
Recently several reports implicate PSPH as a stem cell marker
(Skalnikova et al., 2008). Furthermore PSPH has been identiﬁed
as a gene up-regulated in gastric micrometastasis (Shimomura
et al., 2004). Recently PSPH has been suggested to also be involved
in cell to cell signaling. However we noted an inability to vali-
date our array ﬁnding using a PSPH speciﬁc TaqMan assay. We
explored the reasons for this and noted that the Affymetrix probes
were more likely targeting the poorly described C09 or PSPHL
gene also located on chromosome 7. We were able to conﬁrm the
original array ﬁndings when we used a probe set speciﬁc to PSPHL
and not PSPH.
We noted no functional data in the literature for PSPHL and
were uncertain to the completeness of the annotation. No protein
has been identiﬁed for PSPHL and its function as a non-coding
RNA or as a protein is unknown. Although it contains a region
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of exact homology with PSPH the predicted peptide from the
described genewould encode a very small protein.We further char-
acterized the PSPHL transcript by performing Northern analysis
and found that PSPHL speciﬁc probe targeted a roughly 900 bp
message suggesting that there were not larger PSPHL transcripts.
When we performed PCR on the predicted ORF of PSPHL we
noted two distinct bands. We cloned these and found an alterna-
tive isoform of PSPHL that adds an additional exon and at that
point also changes the open reading frame. We performed 5′ and
3′ RACE and were able to isolate PCR clones representing only
these two splice forms of PSPHL that were predicted to produce
72 or 91 kDa peptides.
Recently Wei et al. (2011) examined the gene expression from
endothelial cells from African-Americans and Caucasians also in
an effort to identify underlying gene expression differences related
to health disparity. They too noted increased PSPHL expression
in endothelial cells in African-Americans and the mis-annotated
PSPH probe set. Furthermore they examined the effect of PSPHL
expression on its enzymatic l-serine phosphatase activity and
found the PSPHL was enzymatically inactive. Additional studies
by them indicated that PSPHLdid not interfere with normal PSPH
activity.
Many cancer sites exhibit racial disparities in outcome and
incidence. Prostate and breast cancers cancer disproportionaltely
affects AA. Similar expression array studies have been performed
for prostate and breast cancers. Wallace et al., identiﬁed PSPHL as
one of the most racially differentially expressed genes in prostate
cancers. Expressionwas higher inAAmen and alongwithCRYBB2
was an accurate two gene classiﬁer for AA status in prostate can-
cer tissue but not corresponding normals (Wallace et al., 2008).
Similarly this same group identiﬁed PSPHL over expression in AA
women compared to CA women’s breast cancers and surround-
ing stroma (Martin et al., 2009). Again PSPHL and CRYBB2 were
demonstrated to be an accurate two gene classiﬁer for AA status
in tumors. PSPHL was one of ﬁve genes necessary to classify the
stroma of these patients.
Importantly we examined whether PSPHL expression was a
tumorderived characteristic orwhether the expressionwas present
prior to neoplastic transforming processes. In two different tis-
sue types uterus and ovary PSPHL was expressed more often
in both normal and malignant tissue from African-Americans.
Indicating that PSPHL expression is not solely a tumor derived
characteristic. This is also supported by the ﬁndings in breast,
prostate, and endothelial cells (Wallace et al., 2008; Martin et al.,
2009; Wei et al., 2011). It also suggests that if PSPHL plays any
role in the racial disparity of endometrial cancer it could affect
numerous processes. Raising the questions of whether presence
of PSPHL actually serve to protect endometrial transformation in
African-Americans where the disease is less prevalent? Or does it
affect some biologic function that could adversely affect outcome
such as drug response, invasion, metastatic spread? Or is PSPHL
expression just reﬂective of an underlying racial difference in gene
expression and have no relation to endometrial cancer. In this
regard we like others could not ﬁnd evidence for a PSPHL peptide
in human cells despite using sophisticated proteomic methods on
cells highly expressing the PSPHL transcript. It is likely if PSPHL
has function in cells it is occurring through an RNA mediated
mechanism. Recently functional roles for LncRNAs have come to
light (Prensner and Chinnaiyan, 2011). The abundance of mRNAs
may also regulate other genes by a ceRNA modulation of miRNA
levels at their 3′ UTRs (Poliseno et al., 2010; Salmena et al., 2011;
Tay et al., 2011). It is clear that future studies are required to assess
the biologic function if any of this transcript.
We did examine two gene expression array datasets with clinical
survival endpoints and designated tissues by race to gain insight on
whetherPSPHL expression is related to survival.We conﬁrmed the
preferential expression of PSPHL in African-Americans as com-
pared to Caucasians cancers in both sets one endometrial and one
ovarian. As we found throughout our studies a signiﬁcant number
of cancers from Caucasian do express PSPHL. This fact allows us
to track survival related to the genes expression rather than using
its expression as a racial surrogate. In these analyses we had access
to a dataset of 133 endometrial cancers of which only 13 expired.
We did not see any association with survival in this set perhaps
reﬂecting the overall good survival in this data set. It will be impor-
tant to analyze the relevance of PSPHL in larger datasets with
more African-Americans and a greater number of adverse sur-
vival events. Similarly we noted a non-signiﬁcant association with
survival in serous ovarian cancers a tumor type generally not asso-
ciated with a racial disparity in outcome. Interestingly we noted
that among the short-term survivors in a large set of advanced
ovarian cancer that PSPHL was highly expressed in AA tumors
although this data was generated from only a few individuals.
In summary we identiﬁed that the PSPHL transcript is differ-
entially expressed in endometrial cancers fromAfrican-Americans
and Caucasians. This tumor type occurs more frequently in Cau-
casians but is more deadly in African-Americans. PSPHL was
also preferentially expressed in normal endometrium of African-
Americans as well as normal and malignant ovary tissues. PSPHL
may ultimately be found to serve as a prognostic marker for these
diseases and could function in numerous cellular processes to
include either tumor suppressionor by affecting biologic andother
treatment events related to outcome.
MATERIALS AND METHODS
PSPHL TRANSCRIPT CHARACTERIZATION
Transcript size was determined by Northern blot of endome-
trial cancer cell line total RNAs isolated from tumor biop-
sies. Transcript speciﬁc 32P labeled probes were generated by
random priming from inserts excised from sequence veriﬁed
vector containing the ORF of PSPHL. Hybridized blots were
washed at high stringency and exposed to phosphor screens.
Phosphor screens were scanned using a Molecular Dynam-
ics STORM (GE Healthcare, UK) phosphorimaging system for
quantitative measurements. PCR primers designed to suspected
PSPHL ORF were ATGGCCAGCGCCAGCTGC and TTATC-
CTTGACTTGTTGCCTGATC. Rapid Ampliﬁcation of cDNA
Ends (SMART RACE) was performed according to the man-
ufacturers recommendations and using a nested primer strat-
egy. 5′ and 3′ cDNAs were prepared from a pool of four uter-
ine carcinomas from African-American women. Primers uti-
lized in 5′ RACE were CCAGCAGCTCTACAAAATCAGTG and
ATTCTTCCGGTTCTCCCAGCAGC. Primers used for 3′ RACE
were ATGGCCAGCGCCAGCTGC (same as ORF above) and
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AAGCTTCTCAATGGCCAGC. PCR products were cloned in
pENTR TOPO vectors (Invitrogen) according to manufacturers
recommendations. Isolated plasmid DNAs were sequenced with
vector based primers M13-F and M13-R.
CELL LINES
AN3CA, KLE, HEC-1-A were obtained from the American Tis-
sue Type Collection, Rockville Md. HEC-59, HOUA, and HHUA
were a kind gift from Hiroyuki Takahashi, Jikei University, Tokyo
Japan. NCI-EC1 was developed by the corresponding author at
the National Cancer Institute (NCI) from a Stage IIIC endometri-
oid cancer. Cells were grown in DMEM/F-12 supplemented with
10% fetal bovine serum and maintained in a humidiﬁed 5% CO2
incubator.
TISSUE SPECIMENS
Flash frozen cancer specimens were obtained from patients under-
going surgery for uterine cancer at Duke University Medical Cen-
ter and were part of a microarray data set previously reported
(Maxwell et al., 2005). All tissues were collected under an IRB
approved protocol at Duke University Medical Center. Specimens
were harvested within 30min of specimen removal at the time
of surgery. Each uterine tumor was then frozen until the time
of the analysis. The set of endometrial cancers selected for this
analysis included 10 African-Americans and 14 Caucasians. Race
determination of patients reﬂected self-described racial status.
Only specimens from African-Americans for which there were
specimens from Caucasians that were matched by stage, grade,
and histology were considered for analysis. Tissue specimens were
evaluated by H&E to conﬁrm that all specimens comprising the
matched pairs contained at least 50% or greater cancer cells. Dur-
ing preparation of the specimens for analysis, care was taken
to macroscopically dissect the cancer away from any adjacent
myometrium. Endometrial, ovarian, and breast samples used for
quantitative PCR validation of array data were obtained from the
cooperative tissue network, Southeast region. Tumor RNAs used
in PSPHL cDNA cloning were obtained from Memorial Health
UniversityMedical center under an approved IRB protocol. Tissue
samples were subjected to RNA isolation following laser capture
of epithelial cell fraction using TRIzol followed by an additional
level of puriﬁcation with the Rneasy Kit (Qiagen, Valencia, CA,
USA). The integrity of each of the RNA samples was conﬁrmed
using denaturing gel electrophoresis.
GENE EXPRESSION ANALYSIS
The gene expressions were assessed using the Affymetrix human
genome HG-U133A and HG-U133B Genechips. Approximately
5μg of total RNA from each sample was labeled using the high
yield transcript labeling kit (ENZO) and labeled RNAs were
hybridized, washed, and scanned according to the manufacturers
speciﬁcations (Affymetrix Inc., Santa Clara, CA,USA). Affymetrix
Microarray Suite 5.0 software (MAS5) was used to estimate tran-
script signal levels from scanned images by one step Tukey’s
biweight algorithm. The signals on each array were normalized
to a trimmed mean value of 500 excluding the lowest 2% and
highest 2% of the signals. An Affymetrix probe set representing
a unique Gene Bank sequence is referred as a transcript here-
after for convenience. Unsupervised data analysis was performed
using Multidimensional scaling where the distance metric was 1-ρ
(ρ is correlation coefﬁcient) and Principal Component Analysis
(PCA) by minimizing the correlations (using R-Statistical pack-
age). About 18,500 transcripts having detection p-value<0.065 in
at least half of the arrays were included in these analyses. Binary
class comparison was performed on the different racial groups
using BRBArray tools software (BRBArray tools ver. 3.0c, Richard
Simon, Amy Peng, Biometric research branch, NCI, NIH2). The
transcripts having detection p-value>0.065 in more than 95% of
the arrays were eliminated for statistical comparisons of classes.
Class comparison using two-sample t -tests between AA and CA
indicated 341 differentially expressed transcripts at p< 0.005. The
signiﬁcance of ﬁnding these 341 transcripts was estimated by a
global test using random permutations of class labels (BRB Array
Tools) which gave a p-value of 0.061. This lack of global differ-
ential expression likely arises from variations in clinical factors.
In order to account for variations in histology, stage and grade,
we considered matched-pair analysis between AA and CA cases.
The matching of 10 AA cases with 14 CA cases resulted in 14
pairs in which four AA cases were duplicated. Class comparison
of these matched pairs by paired t -tests indicated 325 transcripts
at p< 0.005 with a global test p-value of 0.045. There were 66
transcripts altered by twofold among these. Hierarchical cluster-
ing of these transcripts was performed on mean centered gene
expressions using 1-ρ as distance metric and average linkage algo-
rithm (Salmena et al., 2011). The heat map was color-coded using
red for high expression and green for low expression compared
to the array average in black. All the statistical calculations were
performed on the logarithmic values of signals to the base 2. Sur-
vival analysis was done using “survival” package contributed to
R-project3. A uterine cancer data set including 26 AA cases (with
three deaths) and 105 CA cases (with 10 deaths) in a study period
of about 16 years between 1989 and 2007 was used for Kaplan-
Meier plots and for Cox regression analysis. Log-rank and Wald
tests were used to calculate p-values of KM and Cox regression
analyses respectively. Log-rank test of AA vs. CA cases indicated
a p-value of 0.33. Cox proportional hazards regression analysis
indicated poor survival of AA cases at Wald test p-value of 0.34.
There was no signiﬁcant difference in KM curves of the cases hav-
ing PSPHL expression below the median and above the median
level.
VALIDATION OF GENE EXPRESSION USING QUANTITATIVE PCR
The expression of genes chosen for validation were determined by
mulitplex PCR using TaqMan®Gene ExpressionAssays purchased
fromApplied Biosystems, (Foster City,CA,USA)with endogenous
β-actin as reference. Samples were run on the ABI Prism® 7700
SequenceDetection System according tomanufacturer’s suggested
protocols. The relative quantitation was done using the compar-
ative CT threshold cycle (CT) method, and mean of triplicate CT
measurements was calculated for each sample and the ratios to β-
actin were determined. The geometric average of the mean ratios
for each racial group was presented with the standard error of
mean values as error bars.
2http://linus.nci.nih.gov/BRB-ArrayTools.html
3http://www.r-project.org/index.html
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LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
The prominent gel band at 8 kDa was excised and in-gel digested
with trypsin as previously described (Shevchenko et al., 2006).
Peptide digests were analyzed in triplicate by reversed-phase liquid
chromatography (Ultimate 3000, Dionex Corporation, Sunny-
vale, CA, USA) coupled online to a linear ion trap MS (LTQ-
XL, ThermoFisher Scientiﬁc, San Jose, CA, USA) as previously
described (Hood et al., 2010). Tandemmass spectra were searched
against the UniProt human protein database (10/08 release)
from the European Bioinformatics Institute4, using SEQUEST
4http://www.ebi.ac.uk/integr8
(ThermoFisher Scientiﬁc). Additionally, peptides were searched
for methionine oxidation with a mass addition of 15.9949Da.
Peptides were considered legitimately identiﬁed if they met
speciﬁc charge state and proteolytic cleavage-dependent cross
correlation scores of 1.9 for [M+H]1+, 2.2 for [M+ 2H]2+,
and 3.5 for [M+ 3H]3+, and a minimum delta correlation
of 0.08.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Women’s_Cancer/10.3389/
fonc.2012.00065/abstract
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